Twin Tree Management LP Takes Position in uniQure (NASDAQ:QURE)

Twin Tree Management LP purchased a new stake in shares of uniQure (NASDAQ:QURE) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,387 shares of the biotechnology company’s stock, valued at approximately $77,000.

Several other hedge funds have also modified their holdings of QURE. Atria Investments Inc bought a new stake in shares of uniQure during the third quarter valued at approximately $53,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in uniQure in the third quarter valued at approximately $69,000. Charles Schwab Investment Management Inc. boosted its stake in uniQure by 6.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 277,275 shares of the biotechnology company’s stock valued at $1,367,000 after acquiring an additional 16,464 shares during the last quarter. FMR LLC boosted its stake in uniQure by 8,056.6% in the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after acquiring an additional 346,274 shares during the last quarter. Finally, PEAK6 Investments LLC bought a new position in uniQure in the third quarter valued at approximately $260,000. 78.83% of the stock is owned by institutional investors.

uniQure Trading Up 5.5 %

Shares of NASDAQ:QURE opened at $14.04 on Thursday. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The company’s fifty day simple moving average is $13.83 and its 200 day simple moving average is $10.39. The firm has a market cap of $759.24 million, a price-to-earnings ratio of -2.83 and a beta of 0.36.

Insider Buying and Selling

In related news, CFO Christian Klemt sold 2,916 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the sale, the chief financial officer now directly owns 155,168 shares in the company, valued at $1,756,501.76. This trade represents a 1.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Matthew C. Kapusta sold 28,341 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the sale, the chief executive officer now owns 651,454 shares in the company, valued at approximately $6,703,461.66. The trade was a 4.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 90,830 shares of company stock worth $961,401 over the last ninety days. Company insiders own 4.74% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on QURE. Leerink Partners raised their price objective on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. StockNews.com raised shares of uniQure to a “sell” rating in a research note on Tuesday, March 11th. Mizuho raised their price objective on shares of uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 19th. Guggenheim reissued a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price target on shares of uniQure in a research report on Tuesday, January 21st. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $38.89.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.